Drug shortage
Exenatide Synthetic Injectable Suspension · AstraZeneca AB
FDA drug shortage · To Be Discontinued · updated Oct 28, 2024
Key facts
| Generic name | Exenatide Synthetic Injectable Suspension, Extended Release |
|---|---|
| Proprietary name | Bydureon Bcise |
| Company | AstraZeneca AB |
| Presentation | Bydureon Bcise, Injectable Suspension, Extended Release, 2 mg/.85 mL (NDC 0310-6540-04) |
| Dosage form | Extended Release, Injectable Suspension |
| Strength | 2 mg/.85 mL |
| Status | To Be Discontinued |
| Therapeutic category | Endocrinology/Metabolism |
| Package NDCs | 0310-6540-04 |
| First posted | Oct 28, 2024 |
| Last updated | Oct 28, 2024 |
| Discontinued | Oct 28, 2024 |
At a glance
- 1–9 Package NDCs affected
- 1–9 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: